2 not yet recruiting, 1 enrolling by invitation. 1 Early Phase 1, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 1 | Enrolling by invitation 1 |
| Phase 1 | 1 | Not yet recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Liposome Mitoxantrone: new trials by email Literature Review of Liposome Mitoxantrone trials Research Report on Liposome Mitoxantrone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Liposomal Mitoxantrone Plus Azacitidine and Venetoclax in Newly Diagnosed Elderly or Unfit AML Liposome Mitoxantrone, Venetoclax, Azacitidine - Acute Myeloid Leukemia (AML) | Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 30 | 2026-10-30 | 2026-09-18 |
| A Randomized Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid Leukemia Daunorubicin, Cytarabine, Liposome Mitoxantrone - Acute Myeloid Leukemia (AML) | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 320 | 2026-09-30 | 2026-08-26 |
| Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL) targeted AML1-ETO neoantigen cytotoxic T cells (CTL), Cyclophosphamide injection, Decitabine Injection - AML, t(8;21) | Early Phase 1 | Enrolling by invitation | BGI, China | 16 | 2024-02-01 | 2025-08-28 |
Institute of Hematology & Blood Diseases Hospital, China (2) · BGI, China (1)
China (1)